Study on changes in hepatitis B incidence in China, 1990-2017
10.3760/cma.j.cn112338-20201026-01281
- VernacularTitle:中国1990-2017年乙型肝炎疫情的变化趋势研究
- Author:
Zhixi LIU
1
;
Yesheng WANG
;
Weibing WANG
Author Information
1. 复旦大学公共卫生学院流行病学教研室，公共卫生安全教育部重点实验室，上海 200032
- Keywords:
Hepatitis B;
Change trend;
Incidence;
Mortality
- From:
Chinese Journal of Epidemiology
2021;42(4):613-619
- CountryChina
- Language:Chinese
-
Abstract:
Objective:To analyze the changes in the morbidity and mortality of hepatitis B in China from 1990 to 2017, and provide evidence for prevention and control of hepatitis B.Methods:The reported incidence and death data of hepatitis B from the Data-Center of China Public Health Science and demographic data from the National Bureau of Statistics were used, Excel 2016 was used to establish the databases of reported hepatitis B cases and deaths, respectively. The Joinpoint regression model was used through Joinpoint software 4.8.0.1 to estimate the average annual percent change of annual reported incidence and mortality of hepatitis B in different age groups and provinces in China from 1990 to 2017 in order to further explore the trend of hepatitis B incidence. Software R 3.6.2 was used for statistical analysis and data visualization.Results:A total of 20 793 233 hepatitis B cases were reported from January 1990 to December 2017 in China with average annual reported incidence of 58.19/100 000. The average annual reported incidence appeared highest in age group 25-29 years (119.67/100 000) and the annual reported incidence increased in group aged 45 years and above. Besides, the reported case fatality rate reached the highest in group aged 85 years and above (2.26/1 000). The reported incidence showed increasing trends in 23 provinces ( P<0.05), stable in 7 provinces ( P>0.05), and decreasing in 2 provinces ( P<0.05). Conclusions:The report of hepatitis B was mainly from adult population in China, and the reported incidence of hepatitis B in this population was in increase. In some provinces of the eastern China where immunization measures have been in place and the treatment level is relatively high, the incidence of hepatitis B has been leveled off; the incidences in most provinces in western China are still in increase. Therefore, more targeted prevention and control strategies should be taken in different provinces.
